Avadel Pharmaceuticals (AVDL) Operating Leases (2019 - 2022)
Historic Operating Leases for Avadel Pharmaceuticals (AVDL) over the last 4 years, with Q3 2022 value amounting to $1.0 million.
- Avadel Pharmaceuticals' Operating Leases fell 2972.6% to $1.0 million in Q3 2022 from the same period last year, while for Sep 2022 it was $1.0 million, marking a year-over-year decrease of 2972.6%. This contributed to the annual value of $1.7 million for FY2021, which is 722.83% down from last year.
- Latest data reveals that Avadel Pharmaceuticals reported Operating Leases of $1.0 million as of Q3 2022, which was down 2972.6% from $1.3 million recorded in Q2 2022.
- In the past 5 years, Avadel Pharmaceuticals' Operating Leases registered a high of $4.9 million during Q1 2019, and its lowest value of $1.0 million during Q3 2022.
- Moreover, its 4-year median value for Operating Leases was $1.8 million (2020), whereas its average is $2.3 million.
- Its Operating Leases has fluctuated over the past 5 years, first plummeted by 5589.42% in 2020, then crashed by 722.83% in 2021.
- Avadel Pharmaceuticals' Operating Leases (Quarter) stood at $2.3 million in 2019, then fell by 20.66% to $1.8 million in 2020, then dropped by 7.23% to $1.7 million in 2021, then crashed by 39.89% to $1.0 million in 2022.
- Its Operating Leases stands at $1.0 million for Q3 2022, versus $1.3 million for Q2 2022 and $1.5 million for Q1 2022.